Questions/Business/ManagementSTR/571 ASSIGNMENT!!!
PLEASE FIND INSTRUCTION AS ATTACHED.
Attachments
WEEK 6 ASSIGNMENT INSTRUCTIONS.docx
Join now or log in to start viewing answers.
Report DMCA
GregA+ 804 TUTOR Posted 1717. Sold 2312. Solution preview:
Attachments
Infinity pharmaceuticals Presentation.pptx
Infinity pharmaceuticalsInfinity pharmaceuticals
Strategic plans
Executive Summa** *** **** ******* ** **** ****** ** ** investigate ** *** Strategies **** *** ** implemented ** ******** pharmaceuticals ** **** ** *** ******* *** ***** *** objectives ** *** pharmaceutical ******** **** ****** ******* investigates *** background ** *** ***** ******* *** *** acplishments **** *** ***** *** organizations ******** ****** *** ***** statements **** *** **** **** *** ** **** ****** ******* **** *** ******* *** environmental **** ** ******** ** ****** **** **** ******** ** *** ****** *** **** ******** ** *** **** *** ****** ***** ** **** *** strategies ** ** implemented ** *** **** ** achieving *** ****** ****** ** ** *** implementation ****** *** concluding **** *** **** *** **** management ***** *** information ******** ** **** ****** **** **** collected ******* * ******** ***** ******** retrieving information **** * ******* ** ******* *** secondary ******* ** **** ** ****** ******* ******* *** research, **** ******* **** *** **** *** **** ******* ** ****** *** *** ******** *** ******** **** questions **** **** continuously **** ***** ** *** customers ** ******** *** *** potential customers ** **** ** ** ******** **** ******** Pharmaceuticals ** ****** *** implement *** **** strategies ** **** **** ******* ***** pharmaceuticals, *** ** *** *** **** ** *** ***** *****
*
BACKGROUND ** innovative biopharmaceutical organization Discovers, ******** *** ******** ******** ******* ** **** ** ***** ******** *** ****** personnel *** * ****** ** **** ****** ** statement ***** ***** **** ******* *****
******** ** ** innovative biopharmaceutical organization ***** *** established **** *** intention ** discovering, manufacturing *** delivering ******** considered ** ** *** **** ** ***** ** ****** suffering **** ******** ***** *** difficult ** ***** ******** *** **** *** ***** ****** **** ** experienced **** ** professionals *** **** ****** *** **** ** ****** ***** achievements *** ******* ******* ***** ******* *** ******* ** *** ** **** *** **** therapies ** **** peoples ******* ***** ***** *** management ** ****** professionals **** ******* ******** *** ** *** ****** Executive Coordinator, ******** collaborated **** ******* **** * biopharmaceutical ** September **** ** ******* *** mercialize duvelslib, * ******** **** *** *** treatment ** ******* * **** **** *** ****** successful **** **** *** developed * ****** ******* ** ******** ** * ** **** *** *** meaningful medicines *** ***** ******** ****** ****** * ******** Investigator ** ******** ** ** ******* ** *** ****** *** **** *** ******** ** ****** **** medicines *** administered effectively ** ******** ******* ******** ******** beforehand, *** **** ** ******** *** **** (Ballance, ******** * Forstner, ***** ******** Pharmaceuticals *** * ******* ** ******* * **** *** ****** ***** ** ******* ** sustainably discovering, improving *** delivering important *** innovative ******** ** ***** suffering **** ******** ***** *** difficult ** ***** Furthermore, *** **** ***** ** ****** ***** understanding ** *** medicines **** **** discovered ******* ******* ** integration ** *** *** scientific disciplines **** **** **** ** ***** organization ****** ****** *** president ** ******** *** Development ** ******** ******** **** **** Palombella, *** ***** Scientific ******* **** **** *** ***** contributed ** achieving **** ******* ******* *** **** ** *** discovery, preclinical *** ******** development strategies ** ******* medicines ** *** ***** ******** *** * ****** ** attracting * ****** **** ******** *** appreciates ***** ******* ** ******* ******* achieving ****** ***** ** *** medicinal ***** ******** ** ****** ** ****** ** ** ***** **** ****** ** ** ******** ***** ***** ****** *** ** * guideline ** **** *** **** ******* **** *** employers ** **** ** ** ******** * ******* *** *** **** ***** ****** ***** ** *** **** ** statements, *** **** ******** Citizenship- ** ***** *** recognize individual excellence *** ****** ** ** *** ******* ** ******* **** ******* Diversity- ** ******* *** ****** diversity ** * ****** ** creativity *** innovation Transparent Communication- ** ****** *** ****** *** ******* ** knowledge *** **** withholding ** ** ***** ******** unacceptable ****** Responsibility- ** ******** *** ****** *** ******* implications ** *** scientific *** ******** ***** *** practices ****** ****** Integrity- ** ******* **** ******** ***** *** ******** ** *** fundamental ***** *** ******** ***** *** shareholders Passionate Innovation- ** **** *** ******* ** *** ** ***** **** ******* ** ****** ****** ******** ** ***** *** ****** *** ******* ** *** **** ** *** beginning ** ***** discussion; **** *** correctness ** ** ***** *** *** originator, ** *** ****** ** *** ****** *** ** *** *** ** *** discussion, ******* *** *** **** **** **
*
Environmental **** ******** ******* Political ******** ****** Technological Environmental *****
Political ******* *** government possesses * ******* purchasing ***** *** therefore ******* *** **** **** **** ******* *** medicines ** *** ******** ** **** ** *** **** ** ***** medicines ******** therefore ****** ****** ** *** ***** **** **** ** ***** developing countries ** * ***** ***** ** ****** **** *** **** **** ** ** ***** government * ****** ****** ******* ** *** developing countries **** ** ***** manufacturing ***** *** medicine, ******* ******** ** **** ***** ***** ** ***** government **** ******** ******* *** *** ****** ** * ******* ** ****** ******* ** *** pharmaceutical ****** ****** ******* **** ** ** *** *** *** ***** *** ******* *** ******** ** **** *** **** ******* **** ***** ** ******** *** **** ***** *** *** **** representative ****** ** **** (Ballance, ******** * Forstner, ***** Additionally, * **** ******* ****** ** *** **** ** technological advancements ** **** * ****** *** **** professionals ******** *** **** *** ***** ******** **** ****** ** *** ***** ** ******* *** ******** **** ** **** *** *** ** * ******** ** *** unemployment ***** * ******* ****** ** * productive ******* *** * productive ****** ** ** economically ******** ****** ******** *** ****** ** *** ******** *** ** ** **** ** *** ******** condition ** *** ******* ***** **** ******* *** ****** ** ** ******* *** ***** allocation *** ******* ******** *** ****** ** ****** *** **** *** ******* ******* *** **** ** necessary Currently, ** *** wallowing ** *** *** ** ******** ****** *** *** ***** ** ** **** ** **** ***** ** ** *** *** **** * **** ** ******** ****** ****** ******* ****** ******* ****** *** ****** *** ******** ** ******** *** *** ** ******** ****** ******* **** **** *** ** ****** ** ******** *** **** ** ****** problems, ******** ******** population ****** **** ******** ******** *** *** ** ** *** ****** ** **** * **** *** ****** ******** ****** *** *** *** ** *** ***** ****** ******** ** *** developed ******* **** ***** **** *** **** * **** **** *** ***** ** * ******* ***** *** ******** ***** *** *** ** **** ***** ******* ** ***** ****** **** *** **** medicines **** *** **** available ** increased population ****** **** *** *** ** *** ******** ** ****** **** *** *** medicines ******** ** ******** *** ****** population *** **** contributed ** ****** ** ***** ** ** ******** **** ******** *** *** ******* ****** ******* *** ******** association ** ****** **** ****** ***** resistance ** ******** ******* ******* ** ** ******** ** ****** *** ******** Technological ******* **** ****** *** *** ******* ****** ** *** pharmaceutical industryIt ******** innovation *** biotechnology Biotechnology *** **** *** ***** *** * mainstream ** *** ***** ** ******** ** *** **** **** ***** **** ** *** discovery ** *** *** ****** medicines ******** *** * ** **** ***** ***** medicines ******* ******* ****** technologies *** ** **** contributed ** *** production ** **** ******** medicines ***** *** ** ****** ******* *** **** ****** effectiveness **** *** ****** ******** ** *** limelight ** ** ** considered *** ** *** **** pharmaceuticals, *** ** *** **** **** **** ***** ****** ** *** ******** Peoples ***** *** ******* prolonged **** *** production ** **** ******** ******** ** ** *** *** ** **** *** ***** ******* ***** ******* ******** innovation ** *** **** ***** *** **** ** effecting **** technology ** ******* **** **** *** **** especially ** *** **** ** biotechnology **** ***** technological advancements, *** ****** structure *** ** ** ******** ** ***** **** *** *** developments **** ** ******* expensive *** **** consuming *** *** **** Environmental ******* ** *** pharmaceutical industry, *** **** *** environmental ******* ** pollution *** ***** ******** *** ***** ** * ** **** **** ** ******* ****** ******** ****** ** pollution ** *** environment *** environmental ******* *** ******* *** ** pollution ******* ****** ** ******* ******** ******** ******** *** ******* ** * ** **** ******** *** ******* ***** ******** ** **** ** ** ******** **** **** ** *** contribute ** ******* *** environment ** *** *** ******* ***** ***** ******** **** ** ** ***** advantage ** *** **** ** ** increases ****** *** *** **** consequently ***** **** ***** ******* ***** ******* ******* employment **** ******** **** *** ****** **** *** pharmaceutical ******** ** ******* ** regulation, *** *** department *** ** ******* *** *** **** ** ******* *** stability, ****** *** ******** ** ******** ** ****** **** ** ****** *** *** examinations ***** **** ** ******* knowledge *** ** *** **** ** consistent **** *** promotional ***** ** *** **** ****** ** *** **** ******* **** *** employees *** **** **** ******** ***** *** employment **** ******* **** *** employees ****** *** ****** ** *** **** ******** **** *** ** ****** *** ******** ******** ** ******** ** **** *** *** ** ***** ****** *** ** ******* effective ******* providing ***** *** *** consumers ***** Regulations ** *** government *** important ** ******** ******** confidence ** ******** ****** *** stability *** ****** ****** *** **** ****** ******** ** preventing *** ******** ******** **** ******* ****** ** ***** pharmaceuticals
*
******** ******* S-Strengths ** Weaknesses O-Opportunities T-Threats
***** *** *** ******* **** ****** ** **** ****** *** ***** *** *** **** *** ****** ******* **** **** ** ****** * **** ******** ** *** **** ** **** *** *** *** ******* **** ****** Strengths ******** ******** ******** ***** ***** ***** *** **** effective **** ***** ******* counterparts **** *** ****** ** ******** * reputation *** ******* ** *** ****** *** ** * ******* ******** *** ****** **** customers, *** ******** ***** ******** customers Intellectual ******** protection ******* *** ****** protection ******* ******** ** ******* *** ******** ** *** ****** ******** *** * **** ******** **** ******* **** *** Nations boundaries **** ***** countries ** **** ** * **** ******** ** ******** *** ****** ******* *** *** ******* ***** ** ***** ** ******** ****** *** ** *** plimentary ****** ** *** medicines ******** *** continually developed *** ******** ** *** expectations ** *** customers ******** *** ******* ** ******* ** *** increasing ****** ** ******** *** ****** *** ***** ******** ** * ***** ***** *** population ** ******* increasing ******** *** *** **** professionals *** *** ****** knowledgeable *** ****** ** ****** *** **** *** **** ******** Weaknesses Infinitys ******* ** ******** ****** ** sometimes ****** **** published ******* **** ******** *** ******** ** *** **** ** *** ******** **** **** ** ** * ***** ***** ** **** pharmaceutical ****** ******** ** ****** *** ****** *** ******** ***** ** ** ****** **** *** ******** ** collaborate **** universities ** ******* *** ******** **** **** ** production * collaboration **** *** government **** **** *** ** ****** **** ***** ** * continuous ***** ** ****** ** *** materials Opportunities ** **** countries *** expanding ***** ******* *** ******** medicines, *** **** *** * ******** *** delivering ***** ******** Development ** technological ***** **** ******* *** ******** ****** ******* ** * ****** *** professional ******** *** consequently ******* *** ***** ** unemployment *** ******** *** ****** ** population ***** ** ******** ** ****** *** ******** **** *** ****** ** increasing *** ***** *** ******* **** ** ******** *** **** ** environmental ****** ******** *** ***** ******** * ****** ** * ** **** ******** ** ***** ***** ******** ******* ***** *** ******* ******* ******** **** **** ******* ******* **** **** ***** ***** *** **** *** ****** ***** ****** **** *** ******** ******** Incidences ** ******** ******** *** ***** ******* ** * *** ** ****** ** ***** ** *** ***** **** *** **** ******** ** *** ******** *** **** ** ******** *** ****** biotechnology ** ***** expensive *** *** **** **** *** ******** ** *** ******** *** provision ** **** **** ** *** employees increases *** ****** **** ** ****** ******* ** * ******* ** *** businesss ***** ** **** ******* ***** pharmaceuticals ** *** ******** *** ******* ** *** **** ** ******** proportional ** *** ******** ***** ** *** ******* ** **** ** ** ******** instability, *** **** *** **** **** drastically (Geruson, *****
*
Strategies ******* ******** ***** ******** Remendation ** **** ********
** **** ** * **** ** **** *** following strategies *** ******** Pharmaceuticals;
*
****** SEGMENTATION ***** *** consumers *** categorized according ** ***** ******** ***** **** LEADERSHIP ******** ******* * cost-efficient innovative ******** DIFFERENCIATION ******** **** ** ****** ******** ****** *** different **** ***** ****** ** *** ********
******* ******** ***** *** ***** ***** ** strategies **** *** * ******* ** *** **** organization *** ***** *** ** *** ****** segmentation ******** ******* *** organization ******* ** *** ******** ** *** population **** *** organization ***** ******** ****** **** * ******** **** ** ******** ** **** ** recognize ** *** appropriate ***** ** facilities ** amenities *** available *** **** ** *** (Eldering, ***** ** *** **** ** ****** ******** *** ******* *** ******** *** ** categorized ***** ** ***** ***** ** *** ***** ** ****** **** **** *** *** *** * ******** ******** ** ******* ****** *** *** ******** categories *** ****** ******** **** *** ** **** ** *** organization ** *** **** leadership ******** ***** *** ****** *** organization ** ******* innovative technologies **** *** ** **** effective ** *** manufacture ** medications Innovative technologies **** ****** **** ** ***** *** **** ******** *** development **** *** **** effective, *** **** ***** ***** expertise ** *** manufacture ** transformative therapies *** medications (Eldering, ***** Therefore, **** leadership ***** definitely ** ******** *** *** organization ** * ****** ***** *** achievement ** ******* Moreover, **** ******** ***** ******* ****** *** **** ** ******** ******** ******** **** ******** ** ****** ** ******* *** differentiation ******** **** ***** ******** Pharmaceutical ***** * reputation **** **** **** **** ***** *** **** ***** ******** Developing *** therapies *** ***** **** ******* **** ******* ******* * ******** **** ** ****** pharmaceutical ingredient ** *** **** ****** ** ** **** ******* **** * ****** ***** *** **** ** *** ******* ** *** organization (Gru?ne, *** ** addition, ***** *** ** instances **** * particular ******* ** **** ***** *** **** *** ******* * *** *** **** *** ******* * ** **** situations providing variations ** **** particular ******* ** **** **** **** **** *** ***** ** ***** consumers **** differentiation **** *** * ******** *** * reputation *** ******** **** ***** ****** **** **** difficult ** **** ***** *****
*
***** ******** Developing long-term strategic ***** **** *** *** ** **** achievement ***** ******** Marketing Jointcollaborative ******** Development ** organization ** *** ******* Strategic alliances **** ***** pharmaceuticals
***** ******** * ***** ******** **** *** ** ******** ** ******** Pharmaceuticals **** ******* developing * long-term strategic **** ***** *** **** **** ******* ***** ***** ** **** * ****** ** *** pharmaceutical ****** *** ***** ***** objectives, ** *** ** ***** **** approaches **** ** marketing ** ******** development ** organization, diversification ** business, ***** ******* *** ******* ******* strategic ******** ** addition, **** organization ****** ****** partnerships ** ****** ***** resources *** ****** Collaboration **** ******* ****** **** organizations *** including *** ******* government *** non-government organizations *** **** ***** *** ** ******* ****** ******** * collaboration **** ****** educational institutions ** ***** **** *** professionals *** ** ***** increasing ****** *** ******** **** **** *** ** ******** ***** ***** *** ******** ******** *****
*
Remendation *** **** ******** **** Leadership ******** ** *** **** ** ***** ** ******** *** ***** ** ******** ** customers **** customers *** retention ** ******** customers Reduction ** production ****
Remendation *** *** **** ******** *** ***** ******** **** *** ** ******* ** ******** Pharmaceuticals ***** ** *** **** leadership ******** **** ***** ****** *** organization ** ******* ***** *** therapies ** customers ** * ***** ***** ** ***** ** ******* ** *** ***** **** ** ***** ******** ** pharmaceutical ******** *** ** *** ******** ** **** ******** ** **** *** organization **** **** ******** ** *** ******* ** **** ******** ******** ***** ***** *** ** *** ******* ***** ** ** developed, ****** **** * **** ****** ******** advantage ******** ***** ***** ******** ** organization ** *** ****** ***** ******* ** * considerable ****** **** *** ******** ** **** ******** **** ***** ******* *** organization * ***** **** ** achievement ** *** ******* ******* advantage ** **** leadership ******** ** **** ** ***** **** *** organization ** *** * cost-effective organization *** ******* organizational performance **** ******* ** resources *** ******* *** allocated adequately especially ** *** ******** *** development operations
*
******** IMPLEMENTATION ***** Conducting ***** ******* ****** innovative arrangements **** *** **** effective ******* innovative professionals ****** Fostering ** partnerships
Conducting ***** studiesresearch ** ******* ** effective ****** segmentation ***** ****** ** * ******** ***** ******* *** ***** ** implementing *** ****** segmentation **** **** **** **** ** ******** ** ***** ** **** * ******* ******* ** ****** ****** **** Medicines ***** differently ** different individuals **** ****** ** considered ****** *** ******** ******* ** ****** **** *** ***** ******* ****** *** *** ***** ** *** *** segmented categories (Beamish, ***** ****** innovative arrangements **** *** **** effective ******** suffering **** ******** ******** **** ** **** ***** ******* ***** *** **** ***** ** ******** ***** ** therefore * **** *** affordable ***** ** medicines **** *** ** ******** ******* *** ** **** innovative medicines **** *** ******* *** ******* ** ******** technology *** **** **** ******** ******** ****** therefore ****** innovative arrangements **** ***** technological organizations ** **** ******** *** manufacture ** ***** medicines ******* innovative professionals ****** ** **** ** **** ******** *** *** workforce ******* ******** ****** *** ** recruiting professionals regularly ** * ****** ***** *** recruitment ****** ******* individuals *** *** innovative *** passionate ** ****** ** differentiate **** **** **** *** **** Fostering ** partnerships ***** ** *** **** *** ******** ** ****** ***** ****** ** *** ***** ** ******** **** *** ** ******** ******* * collaboration **** ***** ****** ******* providers **** ** hospitals ** ***** ** *** * ******** *** ***** products ****** * partnership **** ** organization **** ** ******** ****** Association ***** *** ******* organizations *** ****** ** providing * ****** *** ***** ******** ******* *** **
*
Effective Communication ****** management ** ******** ****** ******* ******** personnel ***** ** ****
***** *** **** MANAGEMENT ***** organization ** ***** **** *** occurrence ** ***** ******** ** *** ** exception, ******** ** ******* ****** minimizing ***** ** **** ** ******** ***** ** ***** **** ***** **** ******** *** * ** **** * ******* ** **** management ***** ***** ******** ****** munication ******* *** innovators *** *** manufacturers ** ******** *** **** ** misinformation ***** *** **** ******** ***** ***** ****** management ** *** ******* ** ******** ****** **** **** *** ** ****** **** *** decisions **** *** ** ** ***** *** **** *** *** organization, *** stakeholders *** *** *** ***** customers Effective ******** ** personnel ****** **** *** ***** ******** *** **** ******** ***** **** ***** ***** **** ***** **** **** ****** ** ** tolerance ** **** ** *** organization (Porter,****) **** **** **** ** **** **** ****** ***** ***** personnel *** *** ****** knowledgeable *** conversant **** *** ******* *****
**
ReferencesSTRATEGIC PLAN FOR INFINITY PHARMACEUTICALS.docx
STRATEGIC PLAN FOR INFINITY PHARMACEUTICALS **
STRATEGIC PLAN FOR INFINITY PHARMACEUTICALS
**** ** *******
Institutional Affiliation
***** ** ******** Executive ******* * Background * ENVIRONMENTAL **** * ******** Environmental **** ******** * Political ******* * ******** ******* * ****** ******* * Technological ******* * Environmental ******* * ***** ******* * ******** ******* ****** * Weaknesses * Opportunities ** ******* ** ****** ** **** * STRATEGIES ** ******* ******** ** ***** ******** ** Remendation *** *** **** ******** ** ***** *** **** MANAGEMENT ** References **
STRATEGIC **** *** ******** PHARMACEUTICALS
Executive *******
*** **** ******* ** **** ****** ** ** investigate ** *** Strategies **** *** ** implemented ** ******** pharmaceuticals ** **** ** *** ******* *** ***** *** objectives ** *** pharmaceutical ******** **** ****** ******* investigates *** background ** *** ***** ******* *** *** acplishments **** *** ***** *** organizations ******** ****** *** ***** statements **** *** **** **** *** ** **** ****** ******* **** *** ******* *** environmental **** ** ******** ** ****** **** **** ******** ** *** ****** *** **** ******** ** *** **** *** ****** ***** ** **** *** strategies ** ** implemented ** *** **** ** achieving *** ****** ****** ** ** *** implementation ****** *** concluding **** *** **** *** **** management *****
*** information ******** ** **** ****** **** **** collected ******* * ******** ***** ******** retrieving information **** * ******* ** ******* *** secondary ******* ** **** ** ****** ******* ******* *** research, **** ******* **** *** **** *** **** ******* ** ****** *** *** ******** *** ******** **** questions **** **** continuously **** ***** ** *** customers ** ******** *** *** potential customers ** **** ** ** ******** **** ******** Pharmaceuticals ** ****** *** implement *** **** strategies ** **** **** ******* ***** pharmaceuticals, *** ** *** *** **** ** *** ***** *****
Background
******** ** ** innovative biopharmaceutical organization ***** *** established **** *** intention ** discovering, manufacturing *** delivering ******** considered ** ** *** **** ** ***** ** ****** suffering **** ******** ***** *** difficult ** ***** ******** *** **** *** ***** ****** **** ** experienced **** ** professionals *** **** ****** *** **** ** ****** ***** achievements *** ******* ******* ***** ******* *** ******* ** *** ** **** *** **** therapies ** **** peoples ******* ***** ***** *** management ** ****** professionals **** ******* ******** *** ** *** ****** Executive Coordinator, ******** collaborated **** ******* **** * biopharmaceutical ** September **** ** ******* *** mercialize duvelslib, * ******** **** *** *** treatment ** ******* * **** **** *** ****** successful **** **** *** developed * ****** ******* ** ******** ** * ** **** *** *** meaningful medicines *** ***** ******** ****** ****** * ******** Investigator ** ******** ** ** ******* ** *** ****** *** **** *** ******** ** ****** **** medicines *** administered effectively ** ******** ******* ******** ******** beforehand, *** **** ** ******** *** **** (Ballance, ******** * Forstner, *****
******** Pharmaceuticals *** * ******* ** ******* * **** *** ****** ***** ** ******* ** sustainably discovering, improving *** delivering important *** innovative ******** ** ***** suffering **** ******** ***** *** difficult ** ***** Furthermore, *** **** ***** ** ****** ***** understanding ** *** medicines **** **** discovered ******* ******* ** integration ** *** *** scientific disciplines **** **** **** ** ***** organization ****** ****** *** president ** ******** *** Development ** ******** ******** **** **** Palombella, *** ***** Scientific ******* **** **** *** ***** contributed ** achieving **** ******* ******* *** **** ** *** discovery, preclinical *** ******** development strategies ** ******* medicines ** *** ***** ******** *** * ****** ** attracting * ****** **** ******** *** appreciates ***** ******* ** ******* ******* achieving ****** ***** ** *** medicinal *****
******** ** ****** ** ****** ** ** ***** **** ****** ** ** ******** ***** ***** ****** *** ** * guideline ** **** *** **** ******* **** *** employers ** **** ** ** ******** * ******* *** *** **** ***** ****** ***** ** *** **** ** statements, *** **** ********
Citizenship- ** ***** *** recognize individual excellence *** ****** ** ** *** ******* ** ******* **** *******
Diversity- ** ******* *** ****** diversity ** * ****** ** creativity *** innovation
Transparent Communication- ** ****** *** ****** *** ******* ** knowledge *** **** withholding ** ** ***** ******** unacceptable
****** Responsibility- ** ******** *** ****** *** ******* implications ** *** scientific *** ******** ***** *** practices ****** ******
Integrity- ** ******* **** ******** ***** *** ******** ** *** fundamental ***** *** ******** ***** *** shareholders
Passionate Innovation- ** **** *** ******* ** *** ** ***** **** ******* ** ******
****** ******** ** ***** *** ****** *** ******* ** *** **** ** *** beginning ** ***** discussion; **** *** correctness ** ** ***** *** *** originator, ** *** ****** ** *** ****** *** ** *** *** ** *** discussion, ******* *** *** **** ****
ENVIRONMENTAL ****
Political *******
*** government possesses * ******* purchasing ***** *** therefore ******* *** **** **** **** ******* *** medicines ** *** ******** ** **** ** *** **** ** ***** medicines ******** therefore ****** ****** ** *** ***** **** **** ** ***** developing countries ** * ***** ***** ** ****** **** *** **** **** ** ** ***** government * ****** ****** ******* ** *** developing countries **** ** ***** manufacturing ***** *** medicine, ******* ******** ** **** ***** ***** ** ***** government ****
******** *******
*** *** ****** ** * ******* ** ****** ******* ** *** pharmaceutical ****** ****** ******* **** ** ** *** *** *** ***** *** ******* *** ******** ** **** *** **** ******* **** ***** ** ******** *** **** ***** *** *** **** representative ****** ** **** (Ballance, ******** * Forstner, ***** Additionally, * **** ******* ****** ** *** **** ** technological advancements ** **** * ****** *** **** professionals ******** *** **** *** ***** ******** **** ****** ** *** ***** ** ******* *** ******** **** ** **** *** *** ** * ******** ** *** unemployment ***** * ******* ****** ** * productive ******* *** * productive ****** ** ** economically ******** ****** ******** *** ****** ** *** ******** *** ** ** **** ** *** ******** condition ** *** ******* ***** **** ******* *** ****** ** ** ******* *** ***** allocation *** ******* ******** *** ****** ** ****** *** **** *** ******* ******* *** **** ** necessary Currently, ** *** wallowing ** *** *** ** ******** ****** *** *** ***** ** ** **** ** **** ***** ** ** *** *** **** * **** ** ******** ******
****** *******
****** ******* ****** *** ****** *** ******** ** ******** *** *** ** ******** ****** ******* **** **** *** ** ****** ** ******** *** **** ** ****** problems, ******** ******** population ****** **** ******** ******** *** *** ** ** *** ****** ** **** * **** *** ****** ******** ****** *** *** *** ** *** ***** ****** ******** ** *** developed ******* **** ***** **** *** **** * ****
**** *** ***** ** * ******* ***** *** ******** ***** *** *** ** **** ***** ******* ** ***** ****** **** *** **** medicines **** *** **** available ** increased population ****** **** *** *** ** *** ******** ** ****** **** *** *** medicines ******** ** ******** *** ****** population *** **** contributed ** ****** ** ***** ** ** ******** **** ******** *** *** ******* ****** ******* *** ******** association ** ****** **** ****** ***** resistance ** ******** ******* ******* ** ** ******** ** ****** *** ********
Technological *******
**** ****** *** *** ******* ****** ** *** pharmaceutical industryIt ******** innovation *** biotechnology Biotechnology *** **** *** ***** *** * mainstream ** *** ***** ** ******** ** *** **** **** ***** **** ** *** discovery ** *** *** ****** medicines ******** *** * ** **** ***** ***** medicines ******* ******* ****** technologies *** ** **** contributed ** *** production ** **** ******** medicines ***** *** ** ****** ******* *** **** ****** effectiveness **** *** ****** ******** ** *** limelight ** ** ** considered *** ** *** **** pharmaceuticals, *** ** *** **** **** **** ***** ****** ** *** ********
Peoples ***** *** ******* prolonged **** *** production ** **** ******** ******** ** ** *** *** ** **** *** ***** ******* ***** ******* ******** innovation ** *** **** ***** *** **** ** effecting **** technology ** ******* **** **** *** **** especially ** *** **** ** biotechnology **** ***** technological advancements, *** ****** structure *** ** ** ******** ** ***** **** *** *** developments **** ** ******* expensive *** **** consuming *** *** ****
Environmental *******
** *** pharmaceutical industry, *** **** *** environmental ******* ** pollution *** ***** ******** *** ***** ** * ** **** **** ** ******* ****** ******** ****** ** pollution ** *** environment *** environmental ******* *** ******* *** ** pollution ******* ****** ** ******* ******** ******** ******** *** ******* ** * ** **** ******** *** ******* ***** ******** ** **** ** ** ******** **** **** ** *** contribute ** ******* *** environment ** *** *** ******* ***** ***** ******** **** ** ** ***** advantage ** *** **** ** ** increases ****** *** *** **** consequently ***** ****
***** *******
***** ******* ******* employment **** ******** **** *** ****** ****
*** pharmaceutical ******** ** ******* ** regulation, *** *** department *** ** ******* *** *** **** ** ******* *** stability, ****** *** ******** ** ******** ** ****** **** ** ****** *** *** examinations ***** **** ** ******* knowledge *** ** *** **** ** consistent **** *** promotional ***** ** *** **** ****** ** *** **** ******* **** *** employees *** **** **** ******** ***** *** employment **** ******* **** *** employees ****** *** ****** ** *** **** ******** **** *** ** ****** *** ******** ******** ** ******** ** **** *** *** ** ***** ****** *** ** ******* effective ******* providing ***** *** *** consumers ***** Regulations ** *** government *** important ** ******** ******** confidence ** ******** ****** *** stability *** ****** ****** *** **** ****** ******** ** preventing *** ******** ******** **** ******* ****** ** ***** pharmaceuticals
******** ******* ******
***** *** *** ******* **** ****** ** **** ****** *** ***** *** *** **** *** ****** ******* **** **** ** ****** * **** ******** ** *** **** ** **** *** *** *** ******* **** ******
Strengths
******** ******** ******** *****
***** ***** *** **** effective **** ***** ******* counterparts **** *** ****** ** ******** * reputation *** ******* ** *** ****** *** ** * ******* ******** *** ****** **** customers, *** ******** ***** ******** customers
Intellectual ******** protection ******* *** ****** protection ******* ******** ** ******* *** ******** ** *** ******
******** *** * **** ******** **** ******* **** *** Nations boundaries **** ***** countries ** **** ** * **** ******** ** ******** *** ****** ******* *** *** ******* ***** ** ***** ** ******** ****** *** ** *** plimentary ****** ** *** medicines
******** *** continually developed *** ******** ** *** expectations ** *** customers
******** *** ******* ** ******* ** *** increasing ****** ** ******** *** ****** *** ***** ******** ** * ***** ***** *** population ** ******* increasing
******** *** *** **** professionals *** *** ****** knowledgeable *** ****** ** ****** *** **** *** **** ********
Weakn